Who is sponsoring NCT04937972?

NCT04937972 is sponsored by Hunan Province Tumor Hospital.

What drugs are being tested in NCT04937972?

Interventions in NCT04937972: SHR-1701 Combined With Fluazopalil.

What condition does NCT04937972 study?

NCT04937972 studies Non-Small Cell Lung Cancer.

Is NCT04937972 still recruiting?

NCT04937972 is currently status unknown. Last updated 29 December 2023.

Last reviewed 2023-12-29 · How we verify

NCT04937972: FLYFLY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 29 December 2023

What this trial tests

Phase 2 trial testing SHR-1701 Combined With Fluazopalil in Non-Small Cell Lung Cancer in 71 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
1 December 2024

1 June 2025

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	1 July 2021
Primary completion	1 December 2024
Estimated completion	1 June 2025
Sites	1 location across China

Drugs / interventions tested

SHR-1701 Combined With Fluazopalil — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Hunan Province Tumor Hospital

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a first-line treatment maintenance therapy for advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
Advances in molecular pathology and therapy of non-small cell lung cancer.
Huang Q, Li Y, Huang Y, Wu J, et al · · 2025 · cited 43× · PMID 40517166 · DOI 10.1038/s41392-025-02243-6
Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials.
Li L, Wen Q, Ding R. · · 2022 · cited 17× · PMID 35957885 · DOI 10.3389/fonc.2022.905520
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
Quach HT, Hou Z, Bellis RY, Saini JK, et al · · 2022 · cited 5× · PMID 36448335 · DOI 10.1080/13543784.2022.2152323
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment.
Khan SR, Breadner D. · · 2025 · cited 4× · PMID 40277763 · DOI 10.3390/curroncol32040206
Next-generation immunotherapy: igniting new hope for lung cancer.
Li MSC, Chan ALS, Mok KKS, Chan LL, et al · · 2024 · cited 3× · PMID 39649017 · DOI 10.1177/17588359241302021
TGF-β in tumor development and progression: mechanisms and therapeutics.
Liu J, Wang Y, Tang C, Zhang L, et al · · 2026 · cited 1× · PMID 41615651 · DOI 10.1186/s43556-026-00403-w

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04937972 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 29 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing